CDIOW - Cardio Diagnostics Holdings, Inc.
NYSE
$0.02
$-0.00 (-1.20%)
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
CDIOW Key Statistics
Market Cap
$0.00M
Revenue Growth
-0.2%
Employees
15
How CDIOW Compares to Peers
P/E Rank
N/A
of 1
Margin Rank
N/A
of 1
Growth Rank
#2
of 2
Size Rank
N/A
of 1
Cardio Diagnostics Holdings, Inc. Company Information
- Headquarters
- 311 West Superior Street, Chicago, IL, United States, 60654, undefined
- Website
- cdio.ai